The management of renovascular disease: ASTRAL and beyond

Ching M. Cheung, Constantina Chrysochou, Philip A. Kalra

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review: This review concentrates on the new findings published in the atheromatous renovascular disease (ARVD) literature since the beginning of 2009, a period in which the results of two randomized control trials have been released. Recent findings: The key advances have arisen with respect to the epidemiology of ARVD, the effects of revascularization as demonstrated by the results of randomized controlled trials, an understanding of the pathophysiology of the ischaemic kidney, and also there have been further insights regarding the selection of patients for revascularization utilizing structural and functional imaging. Summary: Optimal medical management (and not revascularization therapy) is the established cornerstone for all patients with ARVD. Future studies should be directed to identifying individuals who will significantly benefit from renal revascularization.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalCurrent Opinion in Nephrology & Hypertension
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • ASTRAL trial
  • Atheromatous renovascular disease
  • Magnetic resonance imaging
  • Pathophysiology
  • Renal artery stenosis
  • Renal revascularization

Fingerprint

Dive into the research topics of 'The management of renovascular disease: ASTRAL and beyond'. Together they form a unique fingerprint.

Cite this